EP Med Systems Vs. Echocath Research Paper

To counter these arguments, EchoCath claimed that the numbers they provided were factual. However, given the changes that occurred and the fact that their product was considered to be new / experimental, were signs that this transaction was risky from the beginning (which MedSystems was aware of). As their advisors told them of these possible issues during the initial consultation stages (which are underscoring how the company was aware of these issues early on). (Chrisman, 2001, pp. 201 -- 225) ("EP MedSystems vs. EchoCath," n.d.) After hearing both sides of the arguments, the District Court threw out the lawsuit that was filed by MedSystems. This is because the lower court, believed that the company was aware of: these risks and were liable for the losses (due to the fact that they did not conduct the proper due diligence). However, they appealed the case to United States Court of Appeals. As they reversed the decision of the lower court, by finding that the judge acted improperly in throwing out the lawsuit. With the justices in the U.S. Court of Appeals saying,...

...

EchoCath," n.d.) This is significant, because it shows how the claims made by MedSytems were correct in regards to the actions taken by EchoCath.
Therefore, the results of the case are showing: how all companies need to be able to provide information, that they think is accurate and can be achieved within the stated time frames. This is important, because it is highlighting the basic standards that were used by the Court of Appeals, to determine how various securities laws were violated by EchoCath.

Bibliography

EP MedSystems vs. EthoCath. (n.d.).

Securities Fraud and Insider Trading. (n.d.). 933 -- 934.

Chrisman, R. (2001). Violator Rule 10 b 5. Kentucky Law Journal 89 (1),…

Sources Used in Documents:

Bibliography

EP MedSystems vs. EthoCath. (n.d.).

Securities Fraud and Insider Trading. (n.d.). 933 -- 934.

Chrisman, R. (2001). Violator Rule 10 b 5. Kentucky Law Journal 89 (1), 201 -- 225.


Cite this Document:

"EP Med Systems Vs Echocath" (2011, March 11) Retrieved May 1, 2024, from
https://www.paperdue.com/essay/ep-med-systems-vs-echocath-3806

"EP Med Systems Vs Echocath" 11 March 2011. Web.1 May. 2024. <
https://www.paperdue.com/essay/ep-med-systems-vs-echocath-3806>

"EP Med Systems Vs Echocath", 11 March 2011, Accessed.1 May. 2024,
https://www.paperdue.com/essay/ep-med-systems-vs-echocath-3806

Related Documents

Johnson and Johnson Annual Report Review Financial Report Review Company: Johnson and Johnson Consolidated Balance Sheets Total Assets: $121,347,000,000 Total Liabilities: $56,521,000,000 Total Shareholder's Equity: $64,826,000,000 Company's Retained Earnings: 85,992,000,000 Shares of common stock the company has been authorized to issue: 4,320,000,000 shares Shares the company has issued: 3,119,843,000 shares Cash (cash and cash equivalents): $14,911,000,000 Decrease in cash and cash equivalents during 2012: $9,631,000,000 F: Increase in cash and cash equivalents during 2011: $5,187,000 Consolidated Statement of Earnings Essentially, the term "consolidated" as used

Johnson Bank v. George Korbaken Company Johnson Bank v. George Korbakes Company Over the last several years, the role of the auditor has been continually evolving. This is because financial institutions are relying on the information they are provided with to help them make better choices in the long-term. However, there are times when these firms may not have accurate figures and erroneously report their findings. When this happens, there is a

Johnson and Johnson
PAGES 5 WORDS 1502

Johnson and Johnson Over the last several years, accounting standards and the budgetary process of multinational corporations has been increasingly brought to the forefront. This is because the recent recession and lingering financial challenges, have illustrated how many firms were often over reporting their earnings. As they are using standards that give them more latitude in determining how revenues and expenses are recorded (.i.e. pro-forma). This is when earnings projections and

Johnson Controls Emerging markets are riskier than established ones, and because of that Johnson Controls should make some adjustments to the method by which it evaluates capital investments when dealing in emerging markets. The 2013 Outlook and Strategic Review does not explain how risk is evaluated at Johnson, but the company would normally subject its capital investments to analysis that includes sensitivity analysis, and NPV with sensitivity analysis. For emerging markets, the

Therefore, the claim asserted by Respondents and sustained by the court below would, in practical effect, amount to a right not to be tried at all for an offense against the U.S. armed forces. 339 U.S. 763, 782 (1950). The Court examined the issue of whether the military authorities had jurisdiction to try the offenders. It reasoned that military authorities have had a historical right, during and after hostilities, to

Johnson & Johnson Corporation Johnson and Johnson has been a very broadly-based organization that has been manufacturing health care products since a very long time. It started its footsteps as a child in the mid 1880s with the production of ready-to-use, ready-made surgical dressing. It was the first company to have applied the theory of wound treatment by use of antiseptics. With its application, the chances of infection in postoperative patients